Chapters
Transcript
Episode notes
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27
Introduction
00:00 • 2min
The Banking Question Hasn't Go Away
01:41 • 2min
The Fed's Softening Tone to Stabilize Interest Rates
03:29 • 2min
The Impact of Liquidity on Biotech Stocks
05:18 • 2min
The Rise of Thinly Traded Biotech Companies
07:02 • 1min
Smit Cup Biotech Stocks Are Down or Not Where They Could Be
08:30 • 2min
The Ethics of Making Money From Blockbuster Medicines
10:33 • 4min
The Importance of Communication in a High Stakes Environment
14:54 • 2min
The Fallacy of Government-Funded Research
16:48 • 2min
The Future of R&D Decision Making Process With the IRA Rules
18:18 • 2min
CMS Negotiations: Is It Too Early to Make Strong Decisions?
19:57 • 2min
CMS and the Value Proposition of Drugs
21:34 • 2min
The No-Patient Left Behind Initiative Is a Capital Standard
23:36 • 2min
The Battle Royale of Oral Immunology Drugs
25:58 • 3min
Regeneron and Depixant for COPD: Positive Data for Reduction of Exacerbations and Improvement of FEV1 and Symptoms
28:43 • 2min
The Astellus Data on Clotine 18 Antibodies
30:30 • 4min
Kirt XT for DLBCL Hits on Survival
34:47 • 3min
Sonomaan and the Emerging Two: A Proof of Concept Study
37:44 • 3min
Sedara Therapeutics Gets FDA Approval for an Antifungal Drug
40:27 • 2min
Sedara Approves Candidemia Treatment
42:04 • 3min
The Unmet Medical Need of Anti-Infective Drugs
45:00 • 2min
The Importance of Incentives in Innovation
46:42 • 2min
The Mixed Panel Vote on NFL and Lekenbe
48:20 • 2min
The Role of Neurofilament in Hunter Syndrome
50:42 • 2min
Accelerated Approvals for Gene Therapies
52:20 • 2min
Big Pharma in Major Biotech R&D Amount to 200 Billion Per Year
53:52 • 2min
The Power of Analysis to Predict the Future
55:37 • 3min